Galmed Pharmaceuticals Ltd banner

Galmed Pharmaceuticals Ltd
F:GPH

Watchlist Manager
Galmed Pharmaceuticals Ltd Logo
Galmed Pharmaceuticals Ltd
F:GPH
Watchlist
Price: 2.736 EUR Market Closed
Market Cap: €17.4m

Wall St Price Targets

GPH Price Targets Summary
Galmed Pharmaceuticals Ltd

There are no price targets for GPH.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Galmed Pharmaceuticals Ltd Competitors:
Price Targets
AFYA
Afya Ltd
24% Upside
SANA
Sana Biotechnology Inc
149% Upside
QXO
SilverSun Technologies Inc
104% Upside
SDGR
Schrodinger Inc
7% Upside
IDXX
IDEXX Laboratories Inc
31% Upside
AMP
Amper SA
25% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is GPH's stock price target?
Not Available

GPH does not have any price targets made by Wall Street professionals.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett